SOURCE: Threshold Pharmaceuticals
SOUTH SAN FRANCISCO, CA--(Marketwire - Aug 16, 2012) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Laura G. Hansen, Ph.D., as Senior Director, Corporate Communications. In this role, Dr. Hansen is responsible for heading investor and public relations functions.
Dr. Hansen brings to Threshold 13 years of experience in corporate communications and investor relations in the biotechnology industry. She most recently served as Director, Corporate Communications at FibroGen, Inc., a privately held, development stage biotechnology company. Prior to that, she was Director, Corporate Communications and Investor Relations at Corvas International, Inc. (acquired by Dendreon Corporation). Dr. Hansen began her career in communications at Susan E. Atkins + Associates (acquired by Porter Novelli), an investor and public relations agency focused solely on the biotechnology industry. Dr. Hansen holds a B.S. in Zoology and Ph.D. in Biological Sciences from the University of Texas at Austin.
"We welcome Laura to Threshold and are pleased to have her combined experience in biotechnology communications and background as a scientist," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "I look forward to Laura's contributions in leading our investor and public relations initiatives so that key corporate developments and clinical progress with TH-302 for the treatment of pancreatic and other cancers continue to be communicated in a clear, transparent, and timely manner."
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, Threshold is building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit www.thresholdpharm.com.
Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and their potential therapeutic uses and benefits. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on August 6, 2012 and is available from the SEC's website (www.sec.gov) and on our website (www.thresholdpharm.com) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.